Paradigm Biopharmaceuticals Ltd
ASX:PAR
Intrinsic Value
Paradigm Biopharmaceuticals Ltd. is a biopharmaceutical company, engages in researching and developing therapeutic products for human use. [ Read More ]
The intrinsic value of one
PAR
stock under the Base Case scenario is
1.435
AUD.
Compared to the current market price of 0.285 AUD,
Paradigm Biopharmaceuticals Ltd
is
Undervalued by 80%.
Paradigm Biopharmaceuticals Ltd's market capitalization is 88.3m AUD.
PAR stock price is 0.285 AUD.
PAR stock price (0.285 AUD) is 80% less than its Intrinsic Value (1.435 AUD).
PAR stock price (0.285 AUD) is 86% less than its Relative Value (2.016 AUD). Open Relative Valuation
PAR has upside potential of 377% compared to the average analyst price target.
Open Wall St Estimates
PAR's Revenue has dropped by 3% over the past 12 months.
PAR's ROE (Return on Equity) has significantly decreased in the last 3 years from -33% to -128%, and is approaching profitability.
PAR's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from -469% to -5 233%, and is approaching profitability.
PAR's Revenue has been growing by an exceptional 29% per year for the last 3 years.
PAR has negative Operating Income for the last twelve months.
PAR has negative Net Income for the last twelve months.
PAR's ROE (Return on Equity) for the past 12 months is negative and is equal to -128%.
PAR's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -5 233%.
PAR has positive Gross Profit for the last twelve months.
PAR's Revenue is forecast to grow at a rate of 103% per year over the next 3 years.
PAR has negative Free Cash Flow for the last twelve months.
PAR's short-term assets (42m AUD) exceed its short-term liabilties (11m AUD).
PAR's D/E (Debt to Equity) is very low and is equal to 0.01.
PAR has negative three-year average ROE (Return on Equity): -71%. The company is not efficient at transforming stockholders' equity into net income.
PAR has negative three-year average ROIC (Return on Invested Capital): -1 816%. The company is not efficient at using invested capital to generate operating income.
PAR's long-term assets (45m AUD) exceed its long-term liabilties (11m AUD).
PAR has negative Net Debt. This means that the company has more cash and short-term investments (34m AUD) than debt (177k AUD).
PAR's Altman Z-Score is very low and is equal to -4.22.
PAR earns more than enough operating income (-69m AUD) to safely cover interest payments on its debt (-14k AUD).
Valuation Backtest
Paradigm Biopharmaceuticals Ltd
Run backtest to discover the historical profit from buying and selling
PAR
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Paradigm Biopharmaceuticals Ltd
Balance Sheet Decomposition
Paradigm Biopharmaceuticals Ltd
| Current Assets | 41.8m |
| Cash & Short-Term Investments | 33.6m |
| Receivables | 7.4m |
| Other Current Assets | 850.3k |
| Non-Current Assets | 3.2m |
| PP&E | 263k |
| Intangibles | 2.9m |
| Other Non-Current Assets | -10 |
| Current Liabilities | 10.9m |
| Accounts Payable | 10m |
| Accrued Liabilities | 822.6k |
| Other Current Liabilities | 113.3k |
| Non-Current Liabilities | 317.2k |
| Long-Term Debt | 177k |
| Other Non-Current Liabilities | 140.2k |
Earnings Waterfall
Paradigm Biopharmaceuticals Ltd
|
Revenue
|
8.7m
AUD
|
|
Cost of Revenue
|
-11.5k
AUD
|
|
Gross Profit
|
8.7m
AUD
|
|
Operating Expenses
|
-77.5m
AUD
|
|
Operating Income
|
-68.8m
AUD
|
|
Other Expenses
|
-197.3k
AUD
|
|
Net Income
|
-69m
AUD
|
Free Cash Flow Analysis
Paradigm Biopharmaceuticals Ltd
What is Free Cash Flow?
PAR Profitability Score
Profitability Due Diligence
Paradigm Biopharmaceuticals Ltd's profitability score is 26/100. The higher the profitability score, the more profitable the company is.
Score
Paradigm Biopharmaceuticals Ltd's profitability score is 26/100. The higher the profitability score, the more profitable the company is.
PAR Solvency Score
Solvency Due Diligence
Paradigm Biopharmaceuticals Ltd's solvency score is 79/100. The higher the solvency score, the more solvent the company is.
Score
Paradigm Biopharmaceuticals Ltd's solvency score is 79/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
PAR Price Targets Summary
Paradigm Biopharmaceuticals Ltd
According to Wall Street analysts, the average 1-year price target for
PAR
is 1.36 AUD
.
Shareholder Return
PAR Price
Paradigm Biopharmaceuticals Ltd
| Average Annual Return | 3.91% |
| Standard Deviation of Annual Returns | 51.58% |
| Max Drawdown | -94% |
| Market Capitalization | 88.3m AUD |
| Shares Outstanding | 309 932 000 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Paradigm Biopharmaceuticals Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Paradigm Biopharmaceuticals Ltd. is a biopharmaceutical company, engages in researching and developing therapeutic products for human use. The company is headquartered in Melbourne, Victoria. The company went IPO on 2015-08-19. The firm is developing and commercializing injectable Pentosan Polysulfate Sodium (PPS) for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, aging, degenerative disease, infection, or genetic predisposition. The firm focuses on repurposing PPS for the treatment of Osteoarthritis (OA) and bone marrow lesions (BML), chronic heart failure (CHF) and alphaviral arthritis (Ross River Virus and Chikungunya). Its product candidate PPS is a non-opioid drug treatment for the chronic pain and joint stiffness of Osteoarthritis. Its product candidate PPS is providing treatment for Mucopolysaccharidosis, an inherited defect in the catabolism of sulfated components of connective tissue known as glycosaminoglycans (GAGs). Its product candidate PPS is used to treat Ross River virus and Chikungunya, an arthritogenic alphaviruses transmitted by mosquito bites.
Contact
IPO
Employees
Officers
The intrinsic value of one
PAR
stock under the Base Case scenario is
1.435
AUD.
Compared to the current market price of 0.285 AUD,
Paradigm Biopharmaceuticals Ltd
is
Undervalued by 80%.
You don't have any saved screeners yet
